Gastroparesis Treatment Market Research Report By Treatment Type (Medications, Surgical Interventions, Dietary Management, Electrical Stimulation Devices), By Patient Demographics (Adult, Pediatric, Geriatric), By Route of Administration (Oral, Intravenous, Subcutaneous), By End User (Hospitals, Specialty Clinics, Homecare Settings) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Forecast to 2035

Gastroparesis Treatment Market Overview

As per MRFR analysis, the Gastroparesis Treatment Market Size was estimated at 1.85 (USD Billion) in 2023. The Gastroparesis Treatment Market Industry is expected to grow from 1.95(USD Billion) in 2024 to 3.5 (USD Billion) by 2035. The Gastroparesis Treatment Market CAGR (growth rate) is expected to be around 5.44% during the forecast period (2025 - 2035).

Key Gastroparesis Treatment Market Trends Highlighted

The Global Gastroparesis Treatment Market is witnessing several crucial trends that reflect the evolving landscape of healthcare. One significant trend is the increasing awareness about gastroparesis among both healthcare professionals and patients. This shift is largely driven by a rise in the prevalence of diabetes and other gastrointestinal disorders, which are known to contribute to gastroparesis. Consequently, a growing number of healthcare providers are focusing on early diagnosis and personalized treatment plans to enhance patient outcomes. In recent times, technological advancements in treatment options have emerged as a pivotal market driver.Innovations such as gastric electrical stimulation devices and new pharmacological therapies are becoming more prevalent as patients seek effective symptom management. 

The adoption of minimally invasive surgical techniques is also gaining traction, significantly improving the quality of life for those affected by gastroparesis. There is an opportunity for pharmaceutical companies to expand their research efforts into uncharted territories, such as the development of novel drugs that target the underlying causes of the condition rather than just the symptoms. Furthermore, collaboration between pharmaceutical firms and academic institutions is on the rise, facilitating the exchange of knowledge and resources necessary for developing new treatment modalities.The global focus on enhancing overall healthcare systems presents an opportunity to streamline processes, from diagnosis to treatment accessibility. Overall, the global gastroparesis treatment market is clearly on a path of transformation, with emerging trends and opportunities that show promise in addressing the needs of patients more effectively.

Source: Primary Research, Secondary Research, MRFR Database and Analyst Review

Gastroparesis Treatment Market Drivers

Increasing Prevalence of Gastroparesis

The growing number of gastroparesis cases globally is a major factor driving the global gastroparesis treatment market industry. A National Institutes of Health research estimates that gastroparesis affects 4% of the general population, with a greater frequency observed in people with diabetes. The demand for gastroparesis therapies is expected to expand in tandem with the World Health Organization's (WHO) projection of a 12% increase in diabetes incidence over the past ten years. The need for efficient treatment alternatives is highlighted by this rising occurrence, which supports the expansion of the global gastroparesis treatment market. Additionally, big pharmaceutical companies like Johnson & Johnson and Medtronic are heavily engaged in R&D to provide novel treatments that address this growing patient base, which will have a favorable effect on market dynamics.

Advancements in Treatment Options

The innovation and advancement of treatment methodologies play a crucial role in propelling the Global Gastroparesis Treatment Market Industry. New therapeutic agents and devices, particularly gastric electrical stimulation devices, have shown promising results in managing symptoms effectively. With the United States Food and Drug Administration (FDA) approving the use of these devices, there has been a significant increase in their adoption among healthcare providers.The efficacy of these treatment options is further validated by a clinical trial conducted by the American Gastroenterological Association, indicating symptom improvement in 60% of patients. Pharmaceutical companies like Medtronic have been at the forefront of developing these advanced treatments, underscoring the potential growth within the Global Gastroparesis Treatment Market.

Rising Awareness and Diagnosis of Gastroparesis

The awareness surrounding gastroparesis is steadily increasing, leading to better diagnosis and subsequently boosting the Global Gastroparesis Treatment Market Industry. Educational campaigns led by organizations such as the Gastroparesis Patient Association are providing critical information, leading to earlier recognition of symptoms among patients. Reports indicate that the diagnosis of gastroparesis has risen by about 25% in hospital settings over the past five years as clinicians become more adept at recognizing this underdiagnosed condition.This trend not only promotes patient engagement in seeking treatment but also encourages stakeholders in the healthcare sector, including pharmaceutical firms, to develop targeted therapies, further advancing the market.

Support from Healthcare Policies and Initiatives

Government policies and health initiatives focused on digestive health significantly contribute to the growth of the Global Gastroparesis Treatment Market Industry. National health programs aimed at managing gastrointestinal disorders are gaining traction, with recent initiatives from the Centers for Disease Control and Prevention (CDC) emphasizing the importance of targeted research funding for digestive health. Furthermore, the CDC's 2021 report highlights that approximately 30 million adults in the U.S.Suffer from some form of digestive disorder, prompting healthcare officials to increase resources for treatment approaches. This support from governmental organizations not only enhances Research and Development funding but also incentivizes companies to innovate within the Global Gastroparesis Treatment Market, thus driving its expansion.

Gastroparesis Treatment Market Segment Insights

Gastroparesis Treatment Market Treatment Type Insights

The Global Gastroparesis Treatment Market is segmented based on treatment types, which play a crucial role in addressing this complex gastrointestinal disorder. In 2024, the market for treatment types is valued significantly, with each category contributing to the overall dynamics of the industry. Medications dominate this segment, holding the majority share as they are often the first line of approach for treating gastroparesis; they account for USD 0.9 Billion in 2024 and are projected to reach USD 1.6 Billion by 2035. This growth is primarily driven by the rising prevalence of gastroparesis, increasing awareness, and advancements in pharmaceutical formulations that enhance patient outcomes.

Surgical interventions also hold a significant position in the treatment landscape, valued at USD 0.5 Billion in 2024 and expected to expand to USD 0.9 Billion by 2035. These procedures are often pursued when medication fails, reflecting a growing recognition of surgical options in managing more severe cases of gastroparesis. Dietary management, valued at USD 0.35 Billion in 2024 and anticipated to grow to USD 0.7 Billion by 2035, emphasizes the importance of nutrition and individualized meal plans, which are integral to controlling symptoms and improving the quality of life for patients.Finally, electrical stimulation devices, while currently the smallest segment valued at USD 0.2 Billion in 2024, are gaining traction with innovations that improve gastric functionality. 

These devices are projected to reach USD 0.3 Billion by 2035 as technology develops, providing a promising avenue for treatment in resistant cases. Overall, the Global Gastroparesis Treatment Market segmentation reflects a comprehensive approach to treating this disorder, with each treatment type catering to different patient needs and circumstances, thus positioning the market for sustained growth and resilience in the coming years.The trends towards personalized medicine, rising healthcare expenditures, and increasing support for innovative treatments further enhance the outlook for these treatment types in the Global Gastroparesis Treatment Market.

Source: Primary Research, Secondary Research, MRFR Database and Analyst Review

Gastroparesis Treatment Market Patient Demographics Insights

The Global Gastroparesis Treatment Market, focusing on Patient Demographics, is structured into distinct groups, including Adult, Pediatric, and Geriatric populations. In 2024, the Global Gastroparesis Treatment Market revenue is poised to reach 1.95 USD Billion, reflecting the growing recognition and diagnosis of gastroparesis across various age groups. Adults represent a significant portion of this market, largely due to lifestyle factors and chronic conditions that predispose them to the disease. The Pediatric segment, while smaller, is increasingly important as awareness rises about enteral nutrition needs in young patients.

The Geriatric population presents unique treatment challenges due to comorbidities and polypharmacy, making their needs critical within the Global Gastroparesis Treatment Market segmentation. Understanding these demographics not only facilitates targeted treatment approaches but also highlights the necessity for tailored healthcare solutions to effectively address the specific needs of each age group. The market growth in these segments is propelled by factors like increasing prevalence, advancements in treatment options, and a growing number of healthcare professionals specializing in digestive disorders, further underscoring the importance of tailored care and comprehensive market strategy.

Gastroparesis Treatment Market Route of Administration Insights

The Global Gastroparesis Treatment Market is significantly influenced by the Route of Administration, which plays a crucial role in patient compliance and treatment effectiveness. As the market advances towards a valuation of 1.95 billion USD in 2024, it is pivotal to understand how different routes cater to varying patient needs. The market segmentation primarily comprises Oral, Intravenous, and Subcutaneous administration methods, each serving its unique purpose in delivering therapies. Oral administration is often preferred due to its convenience and ease of use, significantly impacting patient adherence.Intravenous Solution routes are vital in acute care settings where rapid drug action is required, making them essential for severe gastroparesis cases. 

Meanwhile, Subcutaneous routes are becoming increasingly popular due to their ability to self-administer, enhancing patient autonomy and satisfaction. The growth of these segments is driven by continuous advancements in drug formulations and delivery technologies, ensuring improved patient outcomes. As the Global Gastroparesis Treatment Market continues to evolve, understanding these routes’ specific advantages helps define trends and future opportunities within the industry.

Gastroparesis Treatment Market End User Insights

The Global Gastroparesis Treatment Market is experiencing growth driven by its diverse End User segment, which encompasses hospitals, specialty clinics, and homecare settings. In 2024, the overall market is valued at 1.95 billion USD, highlighting a steady interest in gastroparesis management. Hospitals play a crucial role in the treatment landscape due to their comprehensive facilities and access to advanced medical technology. Specialty clinics are also significant as they provide targeted care with a focus on gastrointestinal disorders, often leading to more effective patient outcomes.Homecare settings are increasingly important, enabling patients to receive treatment in a familiar environment and promoting comfort and adherence to therapy. 

The Global Gastroparesis Treatment Market data shows a notable trend towards personalized treatment plans that cater to individual patient needs, particularly at homecare, where convenience and tailored therapies enhance the quality of life. This growing focus on vast healthcare accessibility creates substantial opportunities for all these segments, allowing for a more extensive reach in treating gastroparesis and accommodating the needs of a diverse patient population.With the expected market growth moving towards 3.5 billion USD by 2035, the future outlook for the End User segment remains optimistic, driven by ongoing innovations and improvements in patient care standards.

Gastroparesis Treatment Market Regional Insights

The Global Gastroparesis Treatment Market shows a robust regional landscape, with North America holding the majority, valued at 0.85 USD Billion in 2024 and anticipated to reach 1.45 USD Billion by 2035. This region's prominence is rooted in advanced healthcare infrastructure and increasing awareness of the condition. Europe follows, with a market value of 0.6 USD Billion in 2024, projected to grow to 1.0 USD Billion in 2035, supported by rising healthcare investments and a growing patient population. The Asia-Pacific (APAC) region offers significant potential for growth, valued at 0.3 USD Billion in 2024, and is expected to rise to 0.55 USD Billion by 2035, driven by an expanding middle class and increasing prevalence of gastroparesis.

South America and the Middle East and Africa (MEA) segments, while smaller, contribute to the diversity of the market, with values of 0.1 USD Billion and 0.1 USD Billion in 2024, increasing to 0.15 USD Billion and 0.35 USD Billion respectively by 2035, as these regions see gradual improvements in healthcare accessibility. The various regional valuations reflect a multifaceted market landscape, indicating potential opportunities for growth driven by healthcare advancements and increasing diagnosis rates across these regions.

Source: Primary Research, Secondary Research, MRFR Database and Analyst Review

Gastroparesis Treatment Market Key Players and Competitive Insights

The Global Gastroparesis Treatment Market is evolving significantly, characterized by a range of therapies and medications aimed at managing the symptoms associated with this condition. Gastroparesis, a disorder that affects the stomach muscles and prevents proper stomach emptying, presents substantial challenges not only for patients but also for healthcare providers. The competitive landscape is marked by a variety of pharmaceutical companies and biotechnology firms investing in research and development to introduce effective treatments. Companies are focused on addressing the unmet medical needs associated with gastroparesis, fostering innovation through clinical trials, and creating strategic partnerships to enhance the availability of effective treatment options. 

This sector is further driven by rising awareness of the condition and its management, leading to an increased demand for effective therapies.Pfizer stands out in the Global Gastroparesis Treatment Market due to its established reputation as a leading pharmaceutical giant with a robust product portfolio. The company benefits from its extensive research and development capabilities, which allow it to innovate and bring forth new treatments for conditions like gastroparesis. Pfizer has a global reach, enabling it to effectively distribute its products and ensure accessibility to a wide patient population. The company emphasizes quality as well as safety in its therapeutics, which enhances its credibility within healthcare systems. 

Its extensive experience in navigating regulatory environments and building relationships with healthcare providers further cements its strong position in the market, allowing Pfizer to address the diverse needs of patients suffering from gastroparesis.Xenetic Biosciences is another key player within the Global Gastroparesis Treatment Market, focusing on the development of differentiated therapies for gastrointestinal disorders. The company specializes in novel drug delivery systems that enhance the bioavailability and efficacy of existing medications. Its strong commitment to research has led to the advancement of solutions specifically targeting the mechanisms underlying gastroparesis. 

Xenetic's strategic collaborations and partnerships for the development and commercialization of its therapies bolster its position in the marketplace. The company's strengths include an agile development process and a focus on cutting-edge technologies, which facilitate swift adaptation to market demands. Additionally, ongoing mergers and acquisitions allow Xenetic to enhance its resource capabilities, ensuring the company remains at the forefront of innovation in the global market for gastroparesis treatments.

Key Companies in the Gastroparesis Treatment Market Include

• Pfizer


• Xenetic Biosciences


• Takeda Pharmaceutical


• Zynerba Pharmaceuticals


• AbbVie


• GSK


• Sohum Pharmaceuticals


• Mylan


• Medtronic


• Vanda Pharmaceuticals


• BristolMyers Squibb


• Mallinckrodt Pharmaceuticals


• AstraZeneca


• Eli Lilly and Company

Gastroparesis Treatment Market Industry Developments

Recent developments in the Global Gastroparesis Treatment Market indicate significant activity among leading companies such as Pfizer, AbbVie, and GSK as they continue to advance Research and Development initiatives geared toward innovative therapies. In April 2023, Takeda Pharmaceutical disclosed trial results showing promising efficacy for its new treatment aimed at managing gastroparesis symptoms. The market has also witnessed increased collaboration among firms; in July 2023, Vanda Pharmaceuticals announced a strategic partnership with Mylan to enhance production capabilities for its existing gastroparesis therapies. 

Moreover, AstraZeneca reported notable growth in market valuation due to its aggressive pursuits in expanding its gastrointestinal portfolio. Mergers and acquisitions, an ongoing trend, saw Zynerba Pharmaceuticals acquire select assets from Mallinckrodt Pharmaceuticals aimed at enriching their product lineup in March 2023. The global market is projected to continue its upward trajectory, influenced by the rising prevalence of gastroparesis alongside heightened awareness and diagnosis efforts, making it critical for stakeholders to stay informed about competitive dynamics and regulatory changes impacting this sector.

Gastroparesis Treatment Market Segmentation Insights

Gastroparesis Treatment Market Treatment Type Outlook

• Medications


• Surgical Interventions


• Dietary Management


• Electrical Stimulation Devices

Gastroparesis Treatment Market Patient Demographics Outlook

• Adult


• Pediatric


• Geriatric

Gastroparesis Treatment Market Route of Administration Outlook

• Oral


• Intravenous


• Subcutaneous

Gastroparesis Treatment Market End User Outlook

• Hospitals


• Specialty Clinics


• Homecare Settings

Gastroparesis Treatment Market Regional Outlook

• North America


• Europe


• South America


• Asia Pacific


• Middle East and Africa

Report Attribute/Metric Source:	Details
MARKET SIZE 2023	1.85(USD Billion)
MARKET SIZE 2024	1.95(USD Billion)
MARKET SIZE 2035	3.5(USD Billion)
COMPOUND ANNUAL GROWTH RATE (CAGR)	5.44% (2025 - 2035)
REPORT COVERAGE	Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
BASE YEAR	2024
MARKET FORECAST PERIOD	2025 - 2035
HISTORICAL DATA	2019 - 2024
MARKET FORECAST UNITS	USD Billion
KEY COMPANIES PROFILED	Pfizer, Xenetic Biosciences, Takeda Pharmaceutical, Zynerba Pharmaceuticals, AbbVie, GSK, Sohum Pharmaceuticals, Mylan, Medtronic, Vanda Pharmaceuticals, BristolMyers Squibb, Mallinckrodt Pharmaceuticals, AstraZeneca, Eli Lilly and Company
SEGMENTS COVERED	Treatment Type, Patient Demographics, Route of Administration, End User, Regional
KEY MARKET OPPORTUNITIES	Rising prevalence of diabetes, Increased awareness and diagnosis, Development of novel therapies, Growth in telemedicine solutions, Expansion of nutraceuticals market
KEY MARKET DYNAMICS	Increasing prevalence of gastroparesis, Advancements in treatment options, Rising awareness and diagnosis, Growing geriatric population, High unmet medical needs
COUNTRIES COVERED	North America, Europe, APAC, South America, MEA